Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02349867 · ClinicalTrials.gov registry record · Phase 1
Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer
A Phase 1 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT02349867 is a Phase 1 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 23 participants.
The verdict
NCT02349867, a Phase 1 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
Determine the doses and schedule appropriate for phase 2 study of sorafenib and vorinostat with concurrent gemcitabine and radiation therapy (RT) as neoadjuvant treatment of pancreatic cancer following chemotherapy. Recommended phase II dose RP2Ds and schedule of sorafenib and vorinostat defined as the doses and schedule that are the same as or less than the maximum tolerated dose (MTD) and schedule.
Interventions
- DRUG Gemcitabine
- RADIATION Intensity-Modulated Radiation Therapy
- DRUG Vorinostat
- DRUG Sorafenib
- RADIATION 3-Dimensional Conformal Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2015-01-29 |
| Est. Completion | 2022-05-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02349867
The ClinicalTrials.gov registry entry for NCT02349867 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Gemcitabine is the first listed.
NCT02349867 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02349867 about?
NCT02349867 is a clinical study titled "Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer". Determine the doses and schedule appropriate for phase 2 study of sorafenib and vorinostat with concurrent gemcitabine and radiation therapy (RT) as neoadjuvant treatment of pancreatic cancer following chemotherapy. Recommended phase II dose RP2Ds and schedule of sorafenib and vorinostat defined as ...
What is the current status of trial NCT02349867?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2015-01-29. Estimated completion is 2022-05-13.
What interventions are being tested in trial NCT02349867?
The interventions under investigation include: Gemcitabine (DRUG), Intensity-Modulated Radiation Therapy (RADIATION), Vorinostat (DRUG), Sorafenib (DRUG), 3-Dimensional Conformal Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT02349867?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.